Levine Children's Hospital at Atrium Health, Charlotte, North Carolina;
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia.
Pediatrics. 2020 Jan;145(1). doi: 10.1542/peds.2019-1930.
The tuberculin skin test (TST) has been preferred for screening young children for latent tuberculosis infection (LTBI) because of concerns that interferon-γ release assays (IGRAs) may be less sensitive in this high-risk population. In this study, we compared the predictive value of IGRAs to the TST for progression to tuberculosis disease in children, including those <5 years old.
Children <15 years old at risk for LTBI or progression to disease were tested with TST, QuantiFERON-TB Gold In-Tube test (QFT-GIT), and T-SPOT. test (T-SPOT) and followed actively for 2 years, then with registry matches, to identify incident disease.
Of 3593 children enrolled September 2012 to April 2016, 92% were born outside the United States; 25% were <5 years old. Four children developed tuberculosis over a median 4.3 years of follow-up. Sensitivities for progression to disease for TST and IGRAs were low (50%-75%), with wide confidence intervals (CIs). Specificities for TST, QFT-GIT, and T-SPOT were 73.4% (95% CI: 71.9-74.8), 90.1% (95% CI: 89.1-91.1), and 92.9% (95% CI: 92.0-93.7), respectively. Positive and negative predictive values for TST, QFT-GIT, and T-SPOT were 0.2 (95% CI: 0.1-0.8), 0.9 (95% CI: 0.3-2.5), and 0.8 (95% CI: 0.2-2.9) and 99.9 (95% CI: 99.7-100), 100 (95% CI: 99.8-100), and 99.9 (95% CI: 99.8-100), respectively. Of 533 children with TST-positive, IGRA-negative results not treated for LTBI, including 54 children <2 years old, none developed disease.
Although both types of tests poorly predict disease progression, IGRAs are no less predictive than the TST and offer high specificity and negative predictive values. Results from this study support the use of IGRAs for children, especially those who are not born in the United States.
由于担心干扰素-γ释放试验(IGRAs)在高危人群中的敏感性可能较低,结核菌素皮肤试验(TST)一直被用于筛查儿童潜伏性结核感染(LTBI)。本研究比较了 IGRAs 与 TST 对儿童结核病发病的预测价值,包括年龄<5 岁的儿童。
2012 年 9 月至 2016 年 4 月,对有 LTBI 或发病风险的<15 岁儿童进行 TST、QuantiFERON-TB Gold In-Tube 试验(QFT-GIT)和 T-SPOT. 试验(T-SPOT)检测,并进行为期 2 年的主动随访,然后通过登记匹配,以确定是否发生疾病。
在 3593 名 2012 年 9 月至 2016 年 4 月期间入组的儿童中,92%的儿童出生于美国境外;25%的儿童年龄<5 岁。中位随访 4.3 年后,4 名儿童发生结核病。TST 和 IGRAs 对疾病进展的敏感性较低(50%-75%),置信区间(CI)较宽。TST、QFT-GIT 和 T-SPOT 的特异性分别为 73.4%(95%CI:71.9-74.8)、90.1%(95%CI:89.1-91.1)和 92.9%(95%CI:92.0-93.7)。TST、QFT-GIT 和 T-SPOT 的阳性和阴性预测值分别为 0.2(95%CI:0.1-0.8)、0.9(95%CI:0.3-2.5)和 0.8(95%CI:0.2-2.9)和 99.9(95%CI:99.7-100)、100(95%CI:99.8-100)和 99.9(95%CI:99.8-100)。在 533 名 TST 阳性、IGRA 阴性且未接受 LTBI 治疗的儿童中,包括 54 名年龄<2 岁的儿童,无一例发生疾病。
虽然两种类型的检测都不能很好地预测疾病进展,但 IGRAs 的预测性并不低于 TST,并且具有较高的特异性和阴性预测值。本研究结果支持对儿童,特别是非美国出生的儿童使用 IGRAs。